Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    "Spinocerebellar ataxia 2"
Show Display Options
Rank Status Study
1 Completed Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)
Condition: SPINOCEREBELLAR ATAXIA 2
Intervention: Drug: LITHIUM CARBONATE
2 Unknown  RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7
Condition: Spinocerebellar Ataxias
Intervention:
3 Active, not recruiting Biomarkers in Autosomal Dominant Cerebellar Ataxia
Conditions: Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia, Autosomal Recessive 3;   Episodic Ataxia, Type 7
Intervention: Other: metabolic and imaging biomarkers in SCA1,2,3 and 7 patients
4 Recruiting Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
Conditions: Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 6
Intervention: Genetic: All Participants
5 Completed Dalfampridine and Gait in Spinocerebellar Ataxias
Conditions: Spinocerebellar Ataxias Type 1;   Spinocerebellar Ataxias Type 2;   Spinocerebellar Ataxias Type 3;   Spinocerebellar Ataxias Type 6
Interventions: Drug: Dalfampridine;   Drug: Placebo

Indicates status has not been verified in more than two years